162 related articles for article (PubMed ID: 14959470)
41. Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV.
Bennett MT; Johns KW; Bondy GP
Lipids Health Dis; 2007 Jun; 6():15. PubMed ID: 17565701
[TBL] [Abstract][Full Text] [Related]
42. [Efficacy and tolerability of statins in patients with primary hyperlipidemias].
Rozhkova TA; Susekov AV; Solov'eva EIu; Titov VN; Kukharchuk VV
Kardiologiia; 2005; 45(9):32-4. PubMed ID: 16234790
[No Abstract] [Full Text] [Related]
43. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting.
Bullano MF; Wertz DA; Yang GW; Kamat S; Borok GM; Gandhi S; McDonough KL; Willey VJ
Pharmacotherapy; 2006 Apr; 26(4):469-78. PubMed ID: 16553504
[TBL] [Abstract][Full Text] [Related]
44. Pattern of statins' utilization at Ramathobodi Hospital, 2005 to 2007.
Pattanaprateep O; Pongcharoensuk P; Suvanakoot P; Kaojarern S
J Med Assoc Thai; 2010 Oct; 93(10):1223-31. PubMed ID: 20973328
[TBL] [Abstract][Full Text] [Related]
45. Society already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitution.
Gumbs PD; Verschuren WM; Souverein PC; Mantel-Teeuwisse AK; de Wit GA; de Boer A; Klungel OH
Br J Clin Pharmacol; 2007 Nov; 64(5):680-5. PubMed ID: 17875197
[TBL] [Abstract][Full Text] [Related]
46. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T
Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082
[TBL] [Abstract][Full Text] [Related]
47. Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future.
Godman B; Burkhardt T; Bucsics A; Wettermark B; Wieninger P
Expert Rev Pharmacoecon Outcomes Res; 2009 Oct; 9(5):475-84. PubMed ID: 19817531
[TBL] [Abstract][Full Text] [Related]
48. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients.
Catapano AL; Davidson MH; Ballantyne CM; Brady WE; Gazzara RA; Tomassini JE; Tershakovec AM
Curr Med Res Opin; 2006 Oct; 22(10):2041-53. PubMed ID: 17022864
[TBL] [Abstract][Full Text] [Related]
49. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.
Davidson MH; Stein EA; Bays HE; Maki KC; Doyle RT; Shalwitz RA; Ballantyne CM; Ginsberg HN;
Clin Ther; 2007 Jul; 29(7):1354-67. PubMed ID: 17825687
[TBL] [Abstract][Full Text] [Related]
50. Effectiveness of simvastatin therapy in raising HDL-C in patients with type 2 diabetes and low HDL-C.
Miller M; Dobs A; Yuan Z; Battisti WP; Borisute H; Palmisano J
Curr Med Res Opin; 2004 Jul; 20(7):1087-94. PubMed ID: 15265253
[TBL] [Abstract][Full Text] [Related]
51. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
Stender S; Schuster H; Barter P; Watkins C; Kallend D;
Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
[TBL] [Abstract][Full Text] [Related]
52. Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice.
Visnegarwala F; Maldonado M; Sajja P; Minihan JL; Rodriguez-Barradas MC; Ong O; Lahart CJ; Hasan MQ; Balasubramanyam A; White AC
J Infect; 2004 Nov; 49(4):283-90. PubMed ID: 15474625
[TBL] [Abstract][Full Text] [Related]
53. Serum 1H-nuclear magnetic spectroscopy followed by principal component analysis and hierarchical cluster analysis to demonstrate effects of statins on hyperlipidemic patients.
Le Moyec L; Valensi P; Charniot JC; Hantz E; Albertini JP
NMR Biomed; 2005 Nov; 18(7):421-9. PubMed ID: 16075416
[TBL] [Abstract][Full Text] [Related]
54. Encouraging generic use can yield significant savings.
Zimmerman C
Find Brief; 2012 Nov; 15(8):1-3. PubMed ID: 23213854
[TBL] [Abstract][Full Text] [Related]
55. The benefit of fibrates in the treatment of 'bad HDL-C responders to statins'.
Devroey D; Velkeniers B; Duquet W; Betz W
Int J Cardiol; 2005 May; 101(2):231-5. PubMed ID: 15882669
[TBL] [Abstract][Full Text] [Related]
56. Over-the-counter sales of statins and other drugs for asymptomatic conditions.
Tinetti ME
N Engl J Med; 2008 Jun; 358(25):2728-32. PubMed ID: 18565867
[No Abstract] [Full Text] [Related]
57. Comparative effectiveness of generic and brand-name statins on patient outcomes: a cohort study.
Gagne JJ; Choudhry NK; Kesselheim AS; Polinski JM; Hutchins D; Matlin OS; Brennan TA; Avorn J; Shrank WH
Ann Intern Med; 2014 Sep; 161(6):400-7. PubMed ID: 25222387
[TBL] [Abstract][Full Text] [Related]
58. N-3 fatty acid supplementation decreases plasma homocysteine in diabetic dyslipidemia treated with statin-fibrate combination.
Zeman M; Zák A; Vecka M; Tvrzická E; Písaríková A; Stanková B
J Nutr Biochem; 2006 Jun; 17(6):379-84. PubMed ID: 16214329
[TBL] [Abstract][Full Text] [Related]
59. Simvastatin: two decades in a circle.
Kolovou GD; Katerina A; Ioannis V; Cokkinos DV
Cardiovasc Ther; 2008; 26(2):166-78. PubMed ID: 18485137
[TBL] [Abstract][Full Text] [Related]
60. In Medicare Part D plans, low or zero copays and other features to encourage the use of generic statins work, could save billions.
Hoadley JF; Merrell K; Hargrave E; Summer L
Health Aff (Millwood); 2012 Oct; 31(10):2266-75. PubMed ID: 23048108
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
